Current investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing encouraging effects in addressing obesity and related second-type disease. Animal data suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/